Purine nucleoside analogs in the therapy of cancer and neuroinflammation
2015
Аутори:
Savić, DanijelaStanković, Tijana
Lavrnja, Irena
Podolski-Renić, Ana
Banković, Jasna
Peković, Sanja
Stojiljković, Mirjana
Rakić, Ljubisav
Ruždijić, Sabera
Pešić, Milica
Тип документа:
Приказ (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Purine nucleoside analogs have been in clinical use for almost 50 years. At the beginning developed as antiviral agents, later their efficacy was demonstrated in cancer treatment, especially hematological malignances. The approval of new purine nucleoside analogs by US Food and Drug Administration (FDA) over the past decade implies that the interest for these drugs still exists. Here, we review new nucleoside analogs that are currently in preclinical or clinical development as anticancer agents. In addition, we highlight the potential for implementation of these drugs in other pathological conditions, particularly in neuroinflammation.
Кључне речи:
Purine nucleoside analogs; Cancer; Neuroinflammation; Brain injuryИзвор:
Molecular inhibitors in targeted therapy, 2015, 1, 1, 3-14Финансирање / пројекти:
- Ћелијска и молекулска основа неуроинфламације: потенцијала циљна места за транслациону медицину и терапију (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41014)
- Идентификација молекуларних маркера за предикцију прогресије тумора, одговора на терапију и исхода болести (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41031)
URI
http://www.degruyter.com/view/j/motth.2015.1.issue-1/motth-2015-0002/motth-2015-0002.xmlhttps://radar.ibiss.bg.ac.rs/handle/123456789/2633